Top 5 Stock Picks of Eli Casdin’s Casdin Capital

2. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Casdin Capital’s Stake Value: $117,409,000
Percentage of Casdin Capital’s 13F Portfolio: 9.92%
Number of Hedge Fund Holders: 40

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is a bio-pharmaceutical firm specialising in the discovery, development, and commercialization of new medicines based on ribonucleic acid interference. VenBio Select Advisor held a $198.36 million stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the second quarter consisting of 1.36 million shares, making it the top shareholder of the firm.

After Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) released additional data from the APOLLO-B trial on October 3, Jefferies analyst Maury Raycroft increased his price target on Alnylam to $232 from $218 and reiterated a ‘Buy’ rating on the shares. He reassured the investors by stating that the totality of the research demonstrated consistency of benefit across all sub-groups.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is the second largest stock holding of Eli Casdin’s Casdin Capital as of the second quarter. Casdin owned 805,000 shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) valued at $117.41 million, which represented 9.92% of the fund’s overall portfolio.

40 hedge funds reported bullish bets on Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in Q2 2022, with aggregate holdings worth $775.05 million. In contrast, 38 hedge funds were bullish on the stock a quarter ago.

Follow Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY)